Identifying Novel Genetic Markers Through a Transcription-Wide Association Study: Can This Be a Path to Reducing the Burden of Pancreatic Cancer?
Menée à l'aide de données portant sur des échantillons tissulaires et à partir d'études européennes sur le génome entier de 9 040 patients atteints d'un cancer du pancréas et 12 496 témoins, cette étude d'association sur le transcriptome entier identifie 25 gènes de susceptibilité à la maladie
Pancreatic cancer is one of the most lethal malignancies worldwide, and rates of occurrence and mortality are similar; in 2018, an estimated 458 918 cases of pancreatic cancer occurred globally and 432 242 died from the disease (1). Of those diagnosed with pancreatic cancer, half will die within 6 months, and the 5-year survival for pancreatic cancer is a dismal 8% (2). Another alarming fact is that incidence rates have increased by 1.5% per year since 2004 in the United States (3). Several factors contribute to this high fatality rate, including few known modifiable risk factors, no effective screening tools, and lack of early diagnostic symptoms unique to pancreatic cancer. The exact factors driving this increasing trend in incidence have yet to be elucidated.
Journal of the National Cancer Institute , éditorial en libre accès, 2019